Deutsche Bank Maintains a 'Hold' on Lorillard (LO); Giving Estimates a Lift
Tweet Send to a FriendGet Alerts LO Hot Sheet
Price: $43.98 -2.09%
Rating Summary:
3 Buy, 5 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Rating Summary:
3 Buy, 5 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 22
Trade LO Now!
Deutsche Bank maintains a 'Hold' on Lorillard (NYSE: LO) price target of $131.00 (from $130.00).
Analyst, Andrew Kieley, said, "We are slightly raising estimates based on today’s debt offering, higher leverage target, and share repurchase expectation. We had recently reduced repurchase estimates based on lack of activity, but now assume $500m for FY12 and $700m for 2013. We maintain FY12 EPS at $8.58, raise FY13 $0.02 to $9.39."
"As investors continue to await word on FDA’s menthol review, we note that a recent flurry of FDA conference appearances and press releases on underage tobacco use has not explicitly mentioned menthol at all. We take this as a somewhat positive indicator (and company’s actions today may signal some added confidence), though visibility on FDA intentions remains low."
For an analyst ratings summary and ratings history on Lorillard click here. For more ratings news on Lorillard click here.
Shares of Lorillard closed at $129.00 yesterday, with a 52 week range of $100.76-$141.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Andrew Kieley, said, "We are slightly raising estimates based on today’s debt offering, higher leverage target, and share repurchase expectation. We had recently reduced repurchase estimates based on lack of activity, but now assume $500m for FY12 and $700m for 2013. We maintain FY12 EPS at $8.58, raise FY13 $0.02 to $9.39."
"As investors continue to await word on FDA’s menthol review, we note that a recent flurry of FDA conference appearances and press releases on underage tobacco use has not explicitly mentioned menthol at all. We take this as a somewhat positive indicator (and company’s actions today may signal some added confidence), though visibility on FDA intentions remains low."
For an analyst ratings summary and ratings history on Lorillard click here. For more ratings news on Lorillard click here.
Shares of Lorillard closed at $129.00 yesterday, with a 52 week range of $100.76-$141.07.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: Howard Weil Upgrades LINN Energy (LINE) to Outperform
- UPDATE: UBS Starts Insmed (INSM) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Deutsche Bank, Stock Buyback
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
